Eli Lilly raises 2024 sales forecast on weight-loss drug demand
Share of Eli Lilly surged on their latest Q1 2024 earnings results. Damien Conover, director of healthcare equity research at Morningstar, joins BNN Bloomberg to explain why he still has a sell rating on the stock.